HOME > TOP STORIES

TOP STORIES

REGULATORY PAFSC First Committee Backs Approval of Takeda’s Vonoprazan

November 25, 2014
ORGANIZATION JPMA President Opposes Annual NHI Price Revision

November 21, 2014
REGULATORY Chuikyo OKs NHI Price Listing of 14 APIs/15 Products

November 20, 2014
REGULATORY 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond

November 19, 2014
REGULATORY Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients

November 18, 2014
REGULATORY PMDA to Accept All Requests for Generic Drug Face-to-Face Consultations

November 17, 2014
BUSINESS Combined Half-Year Sales of Major Japanese Drug Makers Up 2.8% Thanks to Overseas Sales

November 14, 2014
REGULATORY New Japan NIH Head Asks Pharma Industry to Suggest Ideas for Benefit of Japanese People

November 13, 2014
BUSINESS Generic Makers Back on Growth Track in First Half of FY2014

November 12, 2014
BUSINESS Kowa Looks to Triple Eye Drug Business with Glanatec

November 11, 2014
BUSINESS Feburic Grabs Top Slot for GP Market in September “Mind Share” Ranking

November 10, 2014
BUSINESS Meiji Seika Pharma Poised to Get Lion’s Share in Antidepressant Market

November 10, 2014
BUSINESS Sales of Four Major Wholesalers Hit by Drop in Long-Listed Product Sales

November 7, 2014
REGULATORY Sept. Drug Price Settlement Rate at 92.6% as Big Hospitals, Pharmacies Take Quantum Leap

November 6, 2014
BUSINESS Overseas Growth Boosts Combined Sales of Four Major Drug Makers

November 6, 2014
TRENDS Chugai Led in Research Grants Payment in FY2013; Grants Fell Among Major Drug Makers

November 5, 2014
BUSINESS Astellas’s First-Half Sales Rise 9.3%, Operating Profit 61.8%

November 4, 2014
BUSINESS Takeda Aims for Consecutive Sales Growth through FY2022

October 31, 2014
BUSINESS GPCR Consortium, an International Partnership of Industry and Academia, Established: Ono

October 30, 2014
ORGANIZATION JPMA to Launch Compound Library Joint Purchasing Initiative; Full-Scale Purchasing to Begin in FY2015

October 29, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…